Clinical trials: Age Related Maculopathy
Macular Degeneration
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
- Trial name
- NCT01362348
- Testing
- pazopanib eye drops
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 19 people
- Sponsor
- GlaxoSmithKline
Age Related Macular Degeneration
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections.
- Trial name
- EXCITE (NCT00275821)
- Testing
- Ranibizumab 0.3 mg - 3 times monthly, then quarterly, Ranibizumab 0.5 mg - 3 times monthly, then quarterly, Ranibizumab 0.3 mg monthly
- Where
- Switzerland
- Volunteers
- 353 people
- Sponsor
- Novartis
Age Related Macular Degeneration
Evaluation of TeleOphthalmology in AMD-TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes
Hypothesis: The use of teleophthalmology for patient screening will result in more rapid patient access for treatment. The use of teleophthalmology to monitor patients with wet AMD post-treatment will result in maintenance of…
- Trial name
- NCT01581606
- Where
- Canada
- Volunteers
- 169 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Age-Related Macular Degeneration (AMD)
A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment.
- Trial name
- NCT00354445
- Testing
- pegaptanib sodium (Macugen)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Eyetech Pharmaceuticals
Intermediate Age-Related Macular Degeneration
QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration
This is a phase 2, randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.
- Trial name
- NCT05562219
- Testing
- QA108 granules
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Smilebiotek Zhuhai Limited
Dry Age-related Macular Degeneration, Geographic Atrophy
Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham injection.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Gene Therapy, Intravitreal Injection
- Trial name
- NCT04358471
- Testing
- Intravitreal AAVCAGsCD59
- Sponsor
- Hemera Biosciences
Neovascular Age-related Macular Degeneration
Vessel Density in nAMD After Longterm Anti-VEGF Treatment Compared to Recently Started Anti-VEGF Treatment
Neovascular age-related macular degeneration (nAMD) is characterized by the abnormal growth of blood vessels from the choroid into the subretinal space which leads to sub- and intraretinal fluid accumulation, hemorrhages and…
- Trial name
- NCT03833830
- Testing
- Optical Coherence Tomography angiography (OCTA)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Dr. med. Katja Hatz
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)
This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III…
- Trial name
- NCT06229665
- Testing
- Valeda Light Delivery System
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- LumiThera, Inc.
Neovascular Age-Related Macular Degeneration
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
Evaluate the safety, tolerability, and efficacy of OTX-TKI for intravitreal use in subjects with Neovascular Age-Related Macular Degeneration
- Trial name
- NCT04989699
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Age-related Macular Degeneration
CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
- Trial name
- CAPTAIN (NCT00500344)
- Testing
- Lucentis (ranibizumab)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Age-related Macular Degeneration, Stress
Assessment of Psychological Strain and Perioperative Fear in Intravitreal Injections
1. Intravitreal injection can induce perioperative stress for the patients. 2. Different factors can modulate the pre-operative fear and physiologic reaction.
- Trial name
- FIVA (NCT00734721)
- Testing
- Preoperative information and perioperative care
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Tuebingen
Age-related Macular Degeneration
Visual Remapping to Aid Reading With Field Loss
Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.
- Trial name
- NCT03848663
- Testing
- Traditional Remapping, Personalized Remapping
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Dry Age Related Macular Degeneration
A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).
- Trial name
- NCT07024732
- Testing
- PST-611
- Where
- 2 sites in France
- Volunteers
- 8 people
- Sponsor
- Eyevensys
Macular Degeneration
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
The purpose of this study is to determine whether injections of rhuFab V2 into the eye can prevent vision loss in patients with age-related macular degeneration, and also to evaluate the safety of this treatment.
- Trial name
- NCT00056836
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 720 people
- Sponsor
- Genentech, Inc.
AMD
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
- Trial name
- NCT00346957
- Testing
- Anecortave acetate 30 mg, Anecortave Acetate 15 mg, Anecortave Acetate 3 mg
- Volunteers
- 128 people
- Sponsor
- Alcon Research
Age Related Macular Degeneration (ARMD)
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD).
- Trial name
- ReNEW (NCT06373731)
- Testing
- Elamipretide
- Where
- 53 sites in United States, Czechia and 6 more
- Volunteers
- 313 people
- Sponsor
- Stealth BioTherapeutics Inc.
AMD
Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD
This is an observational study in which patients affected by dry or wet AMD will be enrolled, after signing the Informed Consent, according to eligibility criteria.
- Trial name
- NCT04177069
- Testing
- Visucomplex Plus
- Where
- 4 sites in Italy
- Volunteers
- 160 people
- Sponsor
- VISUfarma SpA
Age Related Cognitive Decline, Age Related Macular Degeneration
Walnuts and Healthy Aging
This will be a systematic investigation of the role of walnuts in preventing or slowing age related cognitive decline and age related macular degeneration.
- Trial name
- WAHA (NCT01634841)
- Testing
- Walnuts, habitual diet
- Where
- 2 sites in United States, Spain
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- Loma Linda University
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.